| P/E (FY) | — | Sales (TTM) | AUD 8.1M |
| Earnings (TTM) | — | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | — | Trading Days | 5291 |
| 52W High | 6.03 |
| 52W Low | 2.66 |
| % Off High | −24.30% |
| YTD | 48.21% | 1Y | −18.19% |
| 3Y | 55.80% | 5Y | −64.88% |
| 10Y | −89.86% | Since incept. (ann.) | −12.32% |
| Ann. Volatility (1Y) | 63.72% | Ann. Volatility (3Y) | 126.61% |
| Sharpe (1Y) | −0.01 | Sharpe (3Y) | 0.59 |
| Max Drawdown (1Y) | −47.67% | Max Drawdown (3Y) | −75.00% |
| Beta (3Y, vs SPY) | 0.06 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.15T | 53.2 |
| JNJ | JOHNSON & JOHNSON | $642.79B | 24.2 |
| ONC | BeOne Medicines Ltd. | $477.60B | 1739.3 |
| ABBV | AbbVie Inc. | $465.02B | 111.5 |
| MRK | Merck & Co., Inc. | $325.57B | 18.1 |
| ABT | ABBOTT LABORATORIES | $186.84B | 28.8 |
| PFE | PFIZER INC | $143.91B | 18.6 |
| BMY | BRISTOL MYERS SQUIBB CO | $129.88B | 18.4 |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $124.46B | 32.0 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.32B | 16.8 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.25B | 123.8 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $36.88B | 26.2 |
